3.24p
-1.52%
Close of 9 Nov 2026, in pence
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About ImmuPharma
Its shares trade on LSE under the ticker IMM.L. It has been listed since 28 October 2003. In the fiscal year to 31 December 2021, it reported revenue of £118,350 and a net loss of £8.2m. At that date it held total assets of £6.0m and shareholders' equity of £4.4m.
ImmuPharma Plc engages in the research, development, and commercialization of pharmaceutical products. The firm is focused on the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. The firm has approximately five drug candidates in development, over two platform technologies and approximately 70 patents. Lupuzor is the Company's drug candidate and is a treatment for lupus, and life threatening auto immune disease. The firm's treatment for cancer, IPP-204106, has completed a Phase I/IIa study in cancer patients in France. Its compound IPP-102199 for pain relief is designed as a non-addictive replacement for morphine and other opioids, and is in pre-clinical development. Its treatment for inflammatory and allergic disorders (IPP-201007) is in early stage development. Its compound IPP-203101 is an antibiotic against methicillin-resistant staphylococcus aureus (MRSA) and other infections. The firm's research operations are in France.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 28 Oct 2003
- Employees
- 17
- Website
- immupharma.co.uk ↗
Leadership
Pay as last reported
- Mr. Timothy MccarthyExecutive Chairman of the Board, Chief Executive Officer, since 2015£294,000
- Ms. Ashley ClarkeChief Financial Officer and Company Secretary, Executive Director, since 2024
- Dr. Timothy FranklinChief Operating Officer, Executive Director, since 2020£252,000
- Dr. Sebastien GoudreauChief Scientific Officer, Executive Director, since 2023£3,000
- Ms. Lisa BaderoonNon-Executive Director and Head of Investor Relations£132,000
- Dr. Laurence ReillySenior Non-Executive Independent Director£50,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- ImmuPharma PLC has several strengths that contribute to its success in the pharmaceutical industry. Firstly, the company possesses a diverse and innovative product portfolio, which includes drugs aimed at treating different medical conditions. This allows ImmuPharma to cater to a wide range of patient needs and maximize its market potential. Additionally, the company's strong research and development capabilities enable them to continuously enhance and expand their product offerings, staying at the forefront of medical advancements.
Weaknesses
- Despite its strengths, ImmuPharma PLC also faces certain weaknesses that could potentially hinder its growth. One notable weakness is the high dependency on a limited number of key products. If any of these products face regulatory issues or lose market demand, it could significantly impact the company's financial performance and reputation. Moreover, ImmuPharma's relatively smaller size and resource constraints may limit its ability to compete with larger pharmaceutical companies in terms of marketing and distribution capabilities.
Opportunities
- ImmuPharma PLC has several opportunities for further expansion and market penetration. The growing demand for innovative pharmaceutical solutions presents a significant opportunity for the company to introduce new products and capture market share. Additionally, partnerships and collaborations with larger pharmaceutical companies can provide access to additional resources and expertise, enabling ImmuPharma to reach a wider customer base and accelerate the development of new treatments. Expanding into untapped geographic markets and increasing the company's presence in emerging economies are also potential growth opportunities.
Threats
- In a highly competitive pharmaceutical industry, ImmuPharma PLC faces several threats that could impact its performance. One major threat is the presence of generic drug manufacturers, who can offer similar products at lower prices, potentially eroding ImmuPharma's market share. Additionally, stringent regulatory requirements and patent expirations pose challenges in terms of product development and intellectual property protection. Economic uncertainties and fluctuations in exchange rates can also impact the company's financial stability when operating in global markets.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.